JNJ's lockup wrt ACHN shares expired in June 2017—i.e. “sixty days after the first public announcement of top-line clinical results from Janssen’s phase IIb OMEGA-1 clinical trial” [emphasis added]. JNJ reported the top-line results on 4/27/17 (#msg-130712374).
Market Data 
Markets 
AI
